FIRST-IN-HUMAN PHASE 1 STUDY OF TORL-1-23, A NOVEL CLAUDIN 6 (CLDN6) TARGETED ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH OVARIAN CANCER

被引：0
|
作者：
Konecny, Gottfried [1 ]
Hendrickson, Andrea Wahner [2 ]
Winterhoff, Boris [3 ]
Chander, Cinthiya [1 ]
Bilic, Sanela [4 ]
Davenport, Simon [5 ]
Chung, Adrine [6 ]
Miller, Lei-Lani [6 ]
Press, Michael [5 ]
Letrent, Stephen [7 ]
Slamon, Dennis [8 ]
机构：
[1] UCLA, Obstet & Gynecol, Los Angeles, CA USA
[2] Mayo Clin, 200 First St Sw, Rochester, MN USA
[3] Univ Minnesota, Div Gynecol Oncol, Minneapolis, MN USA
[4] Vanadro, Pharmacol, Urbandale, IA USA
[5] Univ Southern Calif, Dept Pathol, Los Angeles, CA USA
[6] Translat Res Oncol US, Clin Operat, Los Angeles, CA USA
[7] TORL Biotherapeut, Clin Dev, Culver City, CA USA
[8] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期
关键词：
D O I：
10.1136/ijgc-2023-IGCS.102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR062
引用
收藏
页码：A67 / A67
页数：1
相关论文
共 50 条
  • [41] A FIRST-IN-HUMAN PHASE 1 STUDY OF NL-201 IN PATIENTS WITH RELAPSED OR REFRACTORY CANCER
    Naing, Aung
    Callahan, Margaret
    Costello, Brian
    Curti, Brendan
    Hall, Evan
    Hansen, Aaron
    Long, Georgina
    Joshua, Anthony
    Shankles, Brooke
    Ulge, Umut
    Ulge, Umut
    Weickhardt, Andrew
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A540 - A540
  • [42] YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
    Zhao, H.
    Ma, Y.
    Meng, X.
    Wu, L.
    Fan, Y.
    Zheng, Y.
    Liu, Z.
    Ji, Y.
    Lv, D.
    Luo, S.
    Sommerhalder, D.
    Fu, S.
    Huang, Y.
    Yang, Y.
    Fang, W.
    Zhao, Y.
    Wang, Y.
    Chin, S.
    Xue, T.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S485 - S485
  • [43] First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
    Kim, Sung-Bae
    Meric-Bernstam, Funda
    Kalyan, Aparna
    Babich, Aleksei
    Liu, Rong
    Tanigawa, Takahiko
    Sommer, Anette
    Osada, Motonobu
    Reetz, Frank
    Laurent, Dirk
    Wittemer-Rump, Sabine
    Berlin, Jordan
    TARGETED ONCOLOGY, 2019, 14 (05) : 591 - 601
  • [44] First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors
    Meric-Bernstam, Funda
    Oh, Do-Youn
    Naito, Yoichi
    Shimizu, Toshio
    Chung, Vincent
    Park, Haeseong
    Gaillard, Stephanie
    Wang, Fujun
    Cooper, Zachary A.
    Kinneer, Krista
    Rebelatto, Marlon
    Kirby, Lyndon
    Luheshi, Nadia
    Miller, Neil
    Varga, Andreea
    Mileshkin, Linda R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] A Phase 1 First-in-Human Single Ascending-dose Study With a Novel Antibody to the Human Thymic Stromal Lymphopoietin Receptor
    Deykin, A.
    Brinkman, C.
    Lloyd, P.
    Becker, O.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [46] First-in-human phase 1 study of a phosphatidylserine-targeting small molecule drug conjugate (T-1201) in patients with advanced solid tumors
    Wang, Hui-Ching
    Yeh, Yu-Min
    Du, Jeng-Shiun
    Yeh, Tsung-Jang
    Tsai, Jui-Hung
    Gau, Yu-Chin
    Wu, Shang Yin
    Chen, Li-Tzong
    Li, Hsiao-Fang
    Su, Wu-Chou
    CANCER RESEARCH, 2024, 84 (07)
  • [47] First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC).
    Kopetz, Scott
    Boni, Valentina
    Kato, Ken
    Raghav, Kanwal Pratap Singh
    Pallis, Athanasios
    Habermehl, Christina
    Galipelli, Srikanth
    Courlet, Perrine
    Rodriguez Rivera, Ildefonso
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors
    Wang, Yong-Sheng
    Jiang, Yu
    Sun, Meili
    Liang, Xu
    Li, Huiping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer.
    Naing, Aung
    Callahan, Margaret
    Costello, Brian A.
    Curti, Brendan
    Hall, Evan
    Hansen, Aaron
    Long, Georgina V.
    Joshua, Anthony M.
    Wetmore, Cynthia
    Weickhardt, Andrew
    CANCER RESEARCH, 2022, 82 (12)
  • [50] A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients.
    Hong, David S.
    Hollebecque, Antoine
    Gordon, Michael S.
    Flaherty, Keith T.
    Shapiro, Geoffrey
    Rodon, Jordi
    Millward, Michael
    Ramdas, Nina
    Zhang, Wei
    Gao, Ling
    Sykes, Amanda
    Willard, Melinda D.
    Yu, Danni
    Schade, Andrew
    Flynn, Daniel Lee
    Kaufman, Michael
    Peng, Sheng-Bin
    Conti, Ilaria
    Tiu, Ramon Velasquez
    Sullivan, Ryan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345